Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Oral Acceptability Trial
NCT00101569Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2004
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Mar 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00101569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101569.